Literature DB >> 19346477

Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates.

John B Robbins1, Joanna Kubler-Kielb, Evguenii Vinogradov, Christopher Mocca, Vince Pozsgay, Joseph Shiloach, Rachel Schneerson.   

Abstract

Shigellosis, an enteric disease, is on the World Health Organization's priority prevention list. In one study, the Shigella sonnei O-specific polysaccharide (O-SP)-protein conjugate showed 72% protection against disease in Israeli army recruits exposed to high rates (8-14%) of infection. The protection was related to vaccine-induced IgG anti-O-SP levels. Synthetic oligosaccharides of Shigella dysenteriae type 1, bound by their reducing ends to a carrier protein ("sun"-type configuration), induced significantly higher antibody levels than the native O-SP bound to protein by multiple-point attachments ("lattice"-type configuration). Attempts to synthesize the S. sonnei O-SP based oligosaccharides were not successful. Here, we describe the isolation, characterization, and conjugation of low-molecular-mass O-SP-core (O-SPC) fragments. The O-SPC fragments were bound by their reducing ends similar to the preparation of the synthetic S. dysenteriae type 1 conjugates. The O-SPC conjugates used oxime linkages between the terminal Kdo residues at the reducing ends of the S. sonnei saccharides and aminooxy linkers bound to BSA or a recombinant diphtheria toxin. The coupling reaction was carried out at a neutral pH and room temperature. IgG antibody levels induced in young outbred mice by the S. sonnei O-SPC conjugates were significantly higher then those elicited by the O-SP conjugates. Accordingly, we propose to evaluate clinically these conjugates.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19346477      PMCID: PMC2683083          DOI: 10.1073/pnas.0900891106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

1.  Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1.

Authors:  V Pozsgay; C Chu; L Pannell; J Wolfe; J B Robbins; R Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  Complete structures of Bordetella bronchiseptica and Bordetella parapertussis lipopolysaccharides.

Authors:  Andrew Preston; Bent O Petersen; Jens Ø Duus; Joanna Kubler-Kielb; Gil Ben-Menachem; Jianjun Li; Evgeny Vinogradov
Journal:  J Biol Chem       Date:  2006-04-21       Impact factor: 5.157

3.  Synthesis of the repeating unit of the O-specific polysaccharide of Shigella sonnei and quantitation of its serologic activity.

Authors:  A Tóth; A Medgyes; I Bajza; A Lipták; G Batta; T Kontrohr; K Péterffy; V Pozsgay
Journal:  Bioorg Med Chem Lett       Date:  2000-01-03       Impact factor: 2.823

4.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

5.  Antibodies against Haemophilus influenzae type b capsular polysaccharide and tetanus toxoid before and after a booster dose of the carrier protein nine years after primary vaccination with a protein conjugate vaccine.

Authors:  Bo A Claesson; Birger Trollfors; Teresa Lagergård; Nina Knutsson; Rachel Schneerson; John B Robbins
Journal:  Pediatr Infect Dis J       Date:  2005-05       Impact factor: 2.129

6.  Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.

Authors:  D Cohen; S Ashkenazi; M S Green; M Gdalevich; G Robin; R Slepon; M Yavzori; N Orr; C Block; I Ashkenazi; J Shemer; D N Taylor; T L Hale; J C Sadoff; D Pavliakova; R Schneerson; J B Robbins
Journal:  Lancet       Date:  1997-01-18       Impact factor: 79.321

7.  The elucidation of the structure of the core part of the LPS from Plesiomonas shigelloides serotype O17 expressing O-polysaccharide chain identical to the Shigella sonnei O-chain.

Authors:  Joanna Kubler-Kielb; Rachel Schneerson; Chris Mocca; Evgeny Vinogradov
Journal:  Carbohydr Res       Date:  2008-09-24       Impact factor: 2.104

8.  Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids.

Authors:  D N Taylor; A C Trofa; J Sadoff; C Chu; D Bryla; J Shiloach; D Cohen; S Ashkenazi; Y Lerman; W Egan
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

9.  Saccharide/protein conjugate vaccines for Bordetella species: preparation of saccharide, development of new conjugation procedures, and physico-chemical and immunological characterization of the conjugates.

Authors:  Joanna Kubler-Kielb; Evgeny Vinogradov; Gil Ben-Menachem; Vince Pozsgay; John B Robbins; Rachel Schneerson
Journal:  Vaccine       Date:  2008-05-20       Impact factor: 3.641

10.  Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice.

Authors:  Vince Pozsgay; Joanna Kubler-Kielb; Rachel Schneerson; John B Robbins
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-28       Impact factor: 11.205

View more
  24 in total

1.  The structure of the Escherichia coli O148 lipopolysaccharide core region and its linkage to the O-specific polysaccharide.

Authors:  Joanna Kubler-Kielb; Wen-Tzu Lai; Rachel Schneerson; Evgeny Vinogradov
Journal:  Carbohydr Res       Date:  2010-10-20       Impact factor: 2.104

Review 2.  Updates on antibody functions in Mycobacterium tuberculosis infection and their relevance for developing a vaccine against tuberculosis.

Authors:  Jacqueline M Achkar; Rafael Prados-Rosales
Journal:  Curr Opin Immunol       Date:  2018-04-12       Impact factor: 7.486

Review 3.  Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.

Authors:  Miguel O'Ryan; Roberto Vidal; Felipe del Canto; Juan Carlos Salazar; David Montero
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Highly homogenous tri-acylated S-LPS acts as a novel clinically applicable vaccine against Shigella flexneri 2a infection.

Authors:  Vladimir A Ledov; Marina E Golovina; Anna A Markina; Yuriy A Knirel; Vyacheslav L L'vov; Alexander L Kovalchuk; Petr G Aparin
Journal:  Vaccine       Date:  2019-01-19       Impact factor: 3.641

5.  Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis.

Authors:  Alan S Cross; Nancy Greenberg; Melissa Billington; Lei Zhang; Christopher DeFilippi; Ryan C May; Kanwaldeep K Bajwa
Journal:  Vaccine       Date:  2015-10-26       Impact factor: 3.641

Review 6.  Shigellosis update: advancing antibiotic resistance, investment empowered vaccine development, and green bananas.

Authors:  Margaret Kosek; Pablo Peñataro Yori; Maribel Paredes Olortegui
Journal:  Curr Opin Infect Dis       Date:  2010-10       Impact factor: 4.915

Review 7.  Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update for 2009-2010.

Authors:  David J Harvey
Journal:  Mass Spectrom Rev       Date:  2014-05-26       Impact factor: 10.946

8.  Immunochemical studies of Shigella flexneri 2a and 6, and Shigella dysenteriae type 1 O-specific polysaccharide-core fragments and their protein conjugates as vaccine candidates.

Authors:  Joanna Kubler-Kielb; Evgeny Vinogradov; Christopher Mocca; Vince Pozsgay; Bruce Coxon; John B Robbins; Rachel Schneerson
Journal:  Carbohydr Res       Date:  2010-05-15       Impact factor: 2.104

9.  Oligosaccharide conjugates of Bordetella pertussis and bronchiseptica induce bactericidal antibodies, an addition to pertussis vaccine.

Authors:  Joanna Kubler-Kielb; Evgeny Vinogradov; Teresa Lagergård; Ariel Ginzberg; Jerry D King; Andrew Preston; Duncan J Maskell; Vince Pozsgay; Jerry M Keith; John B Robbins; Rachel Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-22       Impact factor: 11.205

10.  Circulating Gut-Homing (α4β7+) Plasmablast Responses against Shigella Surface Protein Antigens among Hospitalized Patients with Diarrhea.

Authors:  Anuradha Sinha; Ayan Dey; Giulietta Saletti; Pradip Samanta; Partha Sarathi Chakraborty; M K Bhattacharya; Santanu Ghosh; T Ramamurthy; Jae-Ouk Kim; Jae Seung Yang; Dong Wook Kim; Cecil Czerkinsky; Ranjan K Nandy
Journal:  Clin Vaccine Immunol       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.